Editas Medicine (EDIT) Operating Leases: 2019-2025
Historic Operating Leases for Editas Medicine (EDIT) over the last 7 years, with Sep 2025 value amounting to $13.6 million.
- Editas Medicine's Operating Leases fell 38.61% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year decrease of 38.61%. This contributed to the annual value of $20.4 million for FY2024, which is 16.38% down from last year.
- According to the latest figures from Q3 2025, Editas Medicine's Operating Leases is $13.6 million, which was down 9.51% from $15.0 million recorded in Q2 2025.
- Over the past 5 years, Editas Medicine's Operating Leases peaked at $32.9 million during Q4 2022, and registered a low of $9.3 million during Q3 2022.
- Its 3-year average for Operating Leases is $21.5 million, with a median of $21.8 million in 2024.
- In the last 5 years, Editas Medicine's Operating Leases slumped by 52.50% in 2022 and then skyrocketed by 167.13% in 2023.
- Over the past 5 years, Editas Medicine's Operating Leases (Quarterly) stood at $16.1 million in 2021, then spiked by 104.52% to $32.9 million in 2022, then decreased by 25.84% to $24.4 million in 2023, then fell by 16.38% to $20.4 million in 2024, then crashed by 38.61% to $13.6 million in 2025.
- Its Operating Leases stands at $13.6 million for Q3 2025, versus $15.0 million for Q2 2025 and $18.0 million for Q1 2025.